Martin C. Münchbach
Director/Board Member at YPSOMED HOLDING AG
Net worth: 165 578 $ as of 2024-02-28
Profile
Dr. Martin C.
Münchbach is an Independent Director at Ypsomed Holding AG, a Managing Partner at Pureos Partners AG, a Managing Director at BB Biotech Ventures, a Senior Investment Advisor at Bellevue Asset Management and a Partner at Biotech Ventures GP Ltd.
He is on the Board of Directors at Ariceum Therapeutics GmbH, Ypsomed Holding AG, Tioga Pharmaceuticals, Inc., Alentis Therapeutics AG, Binx Health Ltd., Binx Health, Inc. and BioVascular, Inc. Dr. Münchbach was previously employed as an Independent Director by Radius Health, Inc., an Investment Manager by New Medical Technologies AG, a Partner by BioMedInvest AG I, and a Head-Marketing by Sanofi-Synthélabo SA. He also served on the board at Optimer Pharmaceuticals LLC, Molecular Partners AG, Opsona Therapeutics Ltd.
and Sonetik AG.
He received his graduate degree from Swiss Federal Institute of Technology and a doctorate degree from Swiss Federal Institute of Technology.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
YPSOMED HOLDING AG
0.00% | 2023-03-30 | 400 ( 0.00% ) | 165 578 $ | 2024-02-28 |
Martin C. Münchbach active positions
Companies | Position | Start |
---|---|---|
YPSOMED HOLDING AG | Director/Board Member | 2018-12-31 |
Binx Health Ltd.
Binx Health Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Binx Health, Inc., Binx Health Ltd. engages in research and development on biotechnology. The private company is based in Trowbridge, UK. The British company was founded in 2005. The CEO is Jeffrey R. Luber. | Director/Board Member | 2011-07-18 |
Pureos Partners AG
Pureos Partners AG Investment ManagersFinance Pureos Partners AG is an independent private equity firm founded in 2017 and headquartered in Switzerland. | Private Equity Investor | 2016-12-31 |
Alentis Therapeutics AG
Alentis Therapeutics AG Pharmaceuticals: MajorHealth Technology Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland. | Director/Board Member | - |
BB Biotech Ventures | Chief Executive Officer | 2003-12-31 |
Biotech Ventures GP Ltd.
Biotech Ventures GP Ltd. Financial ConglomeratesFinance Part of Bellevue Group AG, Biotech Ventures GP Ltd. is a venture capital fund. The private company is based in St. Peter Port, UK. | Corporate Officer/Principal | - |
binx health, inc.
binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | Director/Board Member | - |
Tioga Pharmaceuticals, Inc.
Tioga Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tioga Pharmaceuticals, Inc. manufactures pharmaceutical products. It develops therapies for the treatment of pruritus. The company was founded by Stuart J. Collinson in 2005 and is headquartered in San Diego, CA. | Director/Board Member | 2004-12-31 |
Bellevue Asset Management (Venture Capital)
Bellevue Asset Management (Venture Capital) Investment ManagersFinance Bellevue Asset Management (Venture Capital) is the venture capital arm of Bellevue Asset Management AG, a subsidiary of Bellevue Group AG (SW: BBN) headquartered in Zurich, Switzerland. The firm was founded in 1993. | Private Equity Investor | 2003-12-31 |
░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Former positions of Martin C. Münchbach
Companies | Position | End |
---|---|---|
░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
░░░░░░░░░ ░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Training of Martin C. Münchbach
Swiss Federal Institute of Technology | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
MOLECULAR PARTNERS AG | Health Technology |
Private companies | 18 |
---|---|
Sanofi-Synthélabo SA | Health Technology |
Radius Health, Inc.
Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
Tioga Pharmaceuticals, Inc.
Tioga Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tioga Pharmaceuticals, Inc. manufactures pharmaceutical products. It develops therapies for the treatment of pruritus. The company was founded by Stuart J. Collinson in 2005 and is headquartered in San Diego, CA. | Health Technology |
New Medical Technologies AG | Finance |
Ypsomed Holding AG | |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | Health Technology |
BioMedInvest AG I
BioMedInvest AG I Investment ManagersFinance BioMedInvest AG I invests in companies located in Switzerland, Germany, Austria, France and Italy. The fund targets companies operating in the fields of drug development, focusing less on diagnostics and medical technology. It acts as lead/co-lead investor and provides financing for start-up to later stage and spin-off capital requirements with an investment size of CHF1 - CHF10 million. | Finance |
Biotech Ventures GP Ltd.
Biotech Ventures GP Ltd. Financial ConglomeratesFinance Part of Bellevue Group AG, Biotech Ventures GP Ltd. is a venture capital fund. The private company is based in St. Peter Port, UK. | Finance |
BioVascular, Inc.
BioVascular, Inc. Pharmaceuticals: MajorHealth Technology BioVascular, Inc. develops drugs and devices for control of intimal hyperplasia associated with vascular procedures. It is a integrated specialty cardiovascular therapeutic company, and to utilize corporate partnerships in markets that have complex marketing barriers and/or combination technologies. The company was founded by John H. Parrish and Paul F. Glidden in 2005 and is headquartered in San Diego, CA. | Health Technology |
binx health, inc.
binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | Technology Services |
Opsona Therapeutics Ltd.
Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Health Technology |
Bellevue Asset Management (Venture Capital)
Bellevue Asset Management (Venture Capital) Investment ManagersFinance Bellevue Asset Management (Venture Capital) is the venture capital arm of Bellevue Asset Management AG, a subsidiary of Bellevue Group AG (SW: BBN) headquartered in Zurich, Switzerland. The firm was founded in 1993. | Finance |
Sonetik AG
Sonetik AG Medical SpecialtiesHealth Technology Sonetik AG develops and markets digital hearing aids. The firm specializes in the manufacture and distribution of medical aid devices and devices for individuals with hearing impairment or moderate hearing loss. It focuses on the integration of sound processing technologies, such as adaptive directionality, speech recognition, noise reduction, and feedback cancellation. The company was founded by Christian Stromsted in 2007 and is headquartered in Zurich, Switzerland. | Health Technology |
BB Biotech Ventures | |
Pureos Partners AG
Pureos Partners AG Investment ManagersFinance Pureos Partners AG is an independent private equity firm founded in 2017 and headquartered in Switzerland. | Finance |
Binx Health Ltd.
Binx Health Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Binx Health, Inc., Binx Health Ltd. engages in research and development on biotechnology. The private company is based in Trowbridge, UK. The British company was founded in 2005. The CEO is Jeffrey R. Luber. | Commercial Services |
Alentis Therapeutics AG
Alentis Therapeutics AG Pharmaceuticals: MajorHealth Technology Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
Ariceum Therapeutics GmbH
Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | Commercial Services |